RT Journal Article
SR Electronic
T1 A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.27.20202168
DO 10.1101/2020.09.27.20202168
A1 Linssen, Joachim
A1 Ermens, Anthony
A1 Berrevoets, Marvin
A1 Seghezzi, Michela
A1 Previtali, Giulia
A1 Sar-van der Brugge, Simone van der
A1 Russcher, Henk
A1 Verbon, Annelies
A1 Gillis, Judith
A1 Riedl, Jürgen
A1 de Jongh, Eva
A1 Saker, Jarob
A1 Münster, Marion
A1 Munnix, Imke CA
A1 Dofferhoff, Anthonius
A1 Scharnhorst, Volkher
A1 Ammerlaan, Heidi
A1 Deiteren, Kathleen
A1 Bakker, Stephan JL
A1 van Pelt, Lucas Joost
A1 Hingh, Yvette Kluiters-de
A1 Leers, Mathie PG
A1 van der Ven, André
YR 2020
UL http://medrxiv.org/content/early/2020/09/28/2020.09.27.20202168.abstract
AB COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.Competing Interest StatementJoachim Linssen, Jarob Saker and Marion Munster are full-time employees of Sysmex Europe GMBH who provided the study reagents free of charge. Andre van der Ven has an ad hoc consultancy agreement with Sysmex Europe GMBH. All other authors having nothing to declare.Funding StatementSysmex Europe GMBH provided study reagents free of charge to all participating study centres.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by all participating centre ethics committees with approval granted in Italy (Registration Number 54/20) and Belgium (Registration Number 3002020000105) and exemption in the Netherlands, with need for informed consent waived by all.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data files are provided as supplementary material.